The recent approval of Elevidys by the FDA marks it as the first gene therapy approved for the treatment of DMD.[3] Elevidys employs adeno‐associated virus (AAV) vectors to deliver micro‐dystrophin, a 138 kDa protein that encapsulates the functional domains of dystrophin. This evidence concerns the gene DMD and Duchenne muscular dystrophy.